跳至主要内容
临床试验/NCT04585581
NCT04585581进行中(未招募)不适用

Before the Beginning: Preconception Lifestyle Interventions to Improve Future Metabolic Health

Norwegian University of Science and Technology1 个研究点 分布在 1 个国家目标入组 167 人开始时间: 2020年11月6日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
167
试验地点
1
主要终点
Plasma glucose concentration

研究概览

简要总结

The aim of this study is to investigate whether the combination of high intensity exercise and time restricted eating before and during pregnancy can reduce the risk of hyperglycaemia during pregnancy.

详细描述

Women who are planning a pregnancy will be recruited into a parallel groups randomised controlled trial where the intervention will consist of high intensity training and time-restricted eating. The intervention will continue throughout pregnancy. The investigators will assess whether this lifestyle intervention can effect maternal and offspring cardiometabolic health.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 39 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • contemplating pregnancy within the next six months
  • At least one of the following criteria: BMI ≥ 25 < 40 kg/m2, gestational diabetes in a previous pregnancy, previous infant > 4.5 kg, fasting plasma glucose > 5.3 mmol/L, or Non-European ethnicity

排除标准

  • On-going pregnancy
  • Trying to conceive ≥ 6 cycles at study entry
  • Known diabetes (type 1 or 2)
  • Shift work that includes night shifts > 2 days per week
  • Previous hyperemesis
  • Known cardiovascular diseases
  • High intensity exercise ≥ 2 hours/week the last 3 months
  • Habitual eating window ≤ 12 hours

结局指标

主要结局

Plasma glucose concentration

时间窗: Gestational week 28

Plasma glucose concentration after 2 h oral glucose tolerance testing (75 g glucose)

次要结局

  • Head circumference of infant(Delivery)
  • Fat mass(Baseline, intervention week 8, gestational week 12 and 28)
  • Measured physical activity(From baseline and throughout the study period.)
  • Plasma glucose concentration(Gestational week 12)
  • HbA1c(Baseline, intervention week 8, gestational week 12 and 28)
  • Glucose(Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery))
  • Diet intake(Every 8 week throughout the trial.)
  • Insulin(Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery))
  • Cytokines(Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery))
  • Total cholesterol(Baseline, intervention week 8, gestational week 12 and 28)
  • Triglycerides(Baseline, intervention week 8, gestational week 12 and 28)
  • Infant bone mass(Within 72 hours of birth and after 6 weeks post delivery)
  • High density lipoprotein cholesterol(Baseline, intervention week 8, gestational week 12 and 28)
  • Low density lipoprotein cholesterol(Baseline, intervention week 8, gestational week 12 and 28)
  • Low density cholesterol(Baseline, intervention week 8, gestational week 12 and 28)
  • Psychological general well being(Baseline, intervention week 8, gestational week 12 and 28, and every 8 week until delivery or until the participant is excluded from the trial due to not conceiving within 6 months from baseline)
  • Time to pregnancy(From baseline to pregnancy (up to 36 weeks from enrollment))
  • Birth weight (infant)(Delivery)
  • Blood pressure (Infant)(Within 72 hours of birth and after 6 weeks post delivery)
  • Homocysteine(Baseline, intervention week 8, gestational week 12 and 28)
  • Continuous glucose monitoring(Baseline and 8 weeks intervention)
  • Chronotype(Baseline, intervention week 8, gestational week 12 and 28, and every 8 week until delivery or until the participant is excluded from the trial due to not conceiving within 6 months from baseline)
  • Apgar score(Delivery, after 1, 5 and 10 minutes)
  • ICU admission(Delivery)
  • Infant muscle mass(Within 72 hours of birth and after 6 weeks post delivery)
  • Insulin sensitivity(Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery))
  • Muscle mass(Baseline, intervention week 8, gestational week 12 and 28)
  • Psychological well-being(Baseline, intervention week 8, gestational week 12 and 28 and every 8 week throughout the trial.)
  • Cardiac function (Infant)(Within 72 hours of birth and after 6 weeks post delivery)
  • Adipokines (Adiponectin, Leptin, Ghrelin)(Baseline, intervention week 8, gestational week 12 and 28, and in cord blood (delivery))
  • Blood pressure(Baseline, intervention week 8, gestational week 12 and 28)
  • Birth length (infant)(Delivery)
  • Congenital malformation(Delivery)
  • Gestational age at birth(Delivery)
  • Length of stay at hospital(Delivery)
  • Infant total body mass(Within 72 hours of birth and after 6 weeks post delivery)
  • Infant fat mass(Within 72 hours of birth and after 6 weeks post delivery)
  • Infant hydration status(Within 72 hours of birth and after 6 weeks post delivery)
  • Total body mass(Baseline, intervention week 8, gestational week 12 and 28)
  • Visceral fat area(Baseline, intervention week 8, gestational week 12 and 28)
  • Cardiorespiratory fitness(Baseline and intervention week 8)
  • Self-reported physical activity(Baseline, intervention week 8, gestational week 12 and 28, and every 8 week until delivery or until the participant is excluded from the trial due to not conceiving within 6 months from baseline)
  • Sleep(Baseline, intervention week 8, gestational week 12 and 28, and every 8 week until delivery or until the participant is excluded from the trial due to not conceiving within 6 months from baseline)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验